Holen Sie sich die Stockscreener-App
68.12
2.06%
-1.43
Handel nachbörslich:
67.28
-0.84
-1.23%
Schlusskurs vom Vortag:
$69.55
Offen:
$69.77
24-Stunden-Volumen:
920.39K
Relative Volume:
0.64
Marktkapitalisierung:
$4.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.44M
KGV:
-30.68
EPS:
-2.22
Netto-Cashflow:
$-105.32M
1W Leistung:
-0.32%
1M Leistung:
+112.08%
6M Leistung:
+233.27%
1J Leistung:
+141.65%
1-Tages-Spanne:
$65.60
$70.40
1-Wochen-Bereich:
$65.60
$70.40
52-Wochen-Spanne:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Vergleichen Sie GPCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
68.12 | 4.91B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next? - Defense World
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
GPCRStructure Therapeutics Inc ADR Stock Price and Quote - Finviz
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpStill a Buy? - MarketBeat
Why Structure Therapeutics Shares Are Under Pressure Now - TipRanks
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Pfizer (PFE) - The Globe and Mail
Structure Therapeutics begins phase 1 trial of oral obesity drug By Investing.com - Investing.com India
Structure Therapeutics begins phase 1 trial of oral obesity drug - Investing.com
New once-daily obesity pill enters first human tests using amylin biology - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.5%Should You Sell? - MarketBeat
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval - Finviz
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - MarketBeat
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Federated Hermes Inc. Decreases Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics closes $747.5 million public offering - Investing.com
GPCR stock soars 102% on strong phase II obesity data for Aleniglipron - MSN
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by HighVista Strategies LLC - MarketBeat
Structure Therapeutics rises 101.6% - MSN
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? - sharewise.com
Structure Therapeutics Announces $650 Million Public Offering - The Globe and Mail
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics prices upsized $650 million public offering - Investing.com
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewswire Inc.
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial - Finviz
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Discipline and Rules-Based Execution in GPCR Response - news.stocktradersdaily.com
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook - ts2.tech
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - WV News
This trade activity should not be overlooked: Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics stock price target raised to $130 by BMO Capital - Investing.com
Structure Therapeutics stock price target raised to $99 at Clear Street - Investing.com
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More - ts2.tech
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):